Cargando…
Immunotherapy in prostate cancer: current state and future perspectives
Metastatic castrate resistant prostate cancer (PCa) remains an incurable entity. In the era of immunotherapy, the complex PCa microenvironment poses a unique challenge to the successful application of this class of agents. However, in the last decade, a tremendous effort has been made to explore thi...
Autores principales: | Handa, Shivani, Hans, Bandhul, Goel, Shokhi, Bashorun, Hafis O., Dovey, Zach, Tewari, Ashutosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476347/ https://www.ncbi.nlm.nih.gov/pubmed/32952615 http://dx.doi.org/10.1177/1756287220951404 |
Ejemplares similares
-
Unified model involving genomics, magnetic resonance imaging and prostate‐specific antigen density outperforms individual co‐variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer
por: Beksac, Alp Tuna, et al.
Publicado: (2021) -
Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies
por: Dovey, Zachary S., et al.
Publicado: (2021) -
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
por: Crowley, Fionnuala, et al.
Publicado: (2021) -
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
por: Yang, Minfeng, et al.
Publicado: (2020) -
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Voskamp, Marije J., et al.
Publicado: (2021)